^
    2d
    A Study of Patient Characteristics and Treatment Patterns in Real-world Melanoma Patients Treated With Dabrafenib and Trametinib or Encorafenib and Binimetinib in Japan (clinicaltrials.gov)
    P=N/A, N=82, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
    6d
    Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=45 --> 28 | Trial completion date: Jul 2028 --> Jun 2029 | Trial primary completion date: Apr 2028 --> May 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    6d
    Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study. (PubMed, NPJ Precis Oncol)
    Personalized treatment recommendations were made for 13 patients, and 11 received matched therapies: dabrafenib ± trametinib (n = 9), futibatinib (n = 1), or binimetinib (n = 1). These findings demonstrate frequent actionable alterations in ameloblastoma and clinically meaningful responses of targeted therapies. Incorporating precision oncology into standard care may facilitate personalized, less morbid surgery and improved outcomes in these rare tumors.
    Observational data • Journal
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    FGFR2 mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Mektovi (binimetinib) • Lytgobi (futibatinib)
    10d
    BEAVER: Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    13d
    BECOME-MB: Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, UNICANCER | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Keytruda (pembrolizumab) • Mektovi (binimetinib) • Braftovi (encorafenib)
    13d
    A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. (clinicaltrials.gov)
    P1, N=267, Recruiting, Pfizer | Trial completion date: Aug 2030 --> Oct 2029 | Trial primary completion date: Feb 2029 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4)
    |
    BRAF V600E • MSI-H/dMMR
    |
    Erbitux (cetuximab) • 5-fluorouracil • Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • claturafenib (PF-07799933) • midazolam hydrochloride
    14d
    NCI-2020-07748: Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma (clinicaltrials.gov)
    P2, N=25, Recruiting, University of California, San Francisco | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    imatinib • Mektovi (binimetinib)
    24d
    Repurposing the MEK inhibitor binimetinib as a dual anti-inflammatory and antifibrotic agent in pulmonary fibrosis. (PubMed, J Thorac Dis)
    Furthermore, binimetinib attenuated the overall activation of pulmonary macrophages through inhibition of the JAK/STAT pathway. In summary, binimetinib exerted potent anti-inflammatory and antifibrotic effects by suppressing the activation of both fibroblasts and pulmonary macrophages, ultimately mitigating bleomycin-induced pulmonary fibrosis in mice.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Mektovi (binimetinib)
    1m
    Immune checkpoint inhibitor-associated lymphocytic colitis in a patient with metastatic melanoma. (PubMed, BMJ Case Rep)
    We describe the case of a man in his 60s with metastatic melanoma on encorafenib/binimetinib and nivolumab/relatlimab, with a history of immune checkpoint inhibitor (ICI)-induced acute interstitial nephritis, who presented with acute-onset nausea, vomiting and profuse watery diarrhoea. His symptoms persisted despite discontinuation of Braftovi-Mektovi (BRAF-MEK) therapy and required escalation of corticosteroid therapy and budesonide initiation. This case highlights the diagnostic challenges of differentiating ICI-mediated colitis from adverse events of targeted therapy and underscores the importance of endoscopic and histological confirmation in guiding treatment.
    Journal • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    Opdivo (nivolumab) • Mektovi (binimetinib) • Braftovi (encorafenib) • relatlimab (BMS-986016)
    1m
    Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer. (PubMed, Invest New Drugs)
    Despite additive anti-tumor activity for FGFR and MEK inhibition in KRASmt NSCLC lines, the trial was stopped after dose escalation, as no RP2D was identified for futibatinib/binimetinib due to reversible retinopathies. Trial register number. NCT04965818. Trial registration date. 20-September-2021.
    Preclinical • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    KRAS mutation • FGFR2 fusion
    |
    Mektovi (binimetinib) • Lytgobi (futibatinib)
    2ms
    EAY131-Z1A: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Mektovi (binimetinib)
    2ms
    The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials (clinicaltrials.gov)
    P4, N=46, Recruiting, Pfizer | N=71 --> 46
    Enrollment change
    |
    Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib) • Kisqali (ribociclib)